Valuation
- Market cap
- 4,000
- Revenue TTM
- $80,000
- Net income TTM
- $-14,140,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -17,675.00%
- Debt to equity
- 0.00
Trading
- Volume
- 600
- Avg volume
- 4,522
- Day's range
- $0.00 – $0.00
- Shares out
- 40,352,000
- Stochastic %K
- 50%
- Beta
- 0.38
- Analysts
- —
- Price target
- $1.50
Company profile
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sug...
Show more
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 646 416 8000
- Website
- https://nemauramedical.com
- Address
- 57 West 57th Street, Manhattan, New York, United States
Latest news
No headlines yet.
